Exact Mass: 566.2394804
Exact Mass Matches: 566.2394804
Found 500 metabolites which its exact mass value is equals to given mass value 566.2394804
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
100-1
Canescein
Canescein is isolated from Convallaria majalis. Convallaria majalis is banned by the FDA from food use in the US
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
C35H38N2O5 (566.2780577999999)
N-[6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
PA(2:0/6 keto-PGF1alpha)
C25H43O12P (566.2492007999999)
PA(2:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/6 keto-PGF1alpha), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(6 keto-PGF1alpha/2:0)
C25H43O12P (566.2492007999999)
PA(6 keto-PGF1alpha/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/2:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/TXB2)
C25H43O12P (566.2492007999999)
PA(2:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/TXB2), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(TXB2/2:0)
C25H43O12P (566.2492007999999)
PA(TXB2/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/2:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
(5S,6R,7R,8S)-2-(2-Phenylethyl)-5,6,7-tri-hydroxy-5,6,7,8-tetrahydro-8-[2-(2-phenylethyl)chromonyl-6-oxy]chromone (AH13)|(5S,6R,7R,8S)-2-(2-phenylethyl)-5,6,7-trihydroxy-5,6,7,8-tetrahydro-8-<2-(2-phenylethyl)chromonyl-6-oxy>chromone|(5S,6R,7R,8S)-2-(2-phenylethyl)-5,6,7-trihydroxy-5,6,7,8-tetrahydro-8-[2-(2-phenylethyl)chromonyl-6-oxy]chromone|AH13
(3S,5S,10S,13R,14S,17R)-5,14-dihydroxy-13-methyl-17-(5-oxo-2H-furan-3-yl)-3-[(2R,5S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-10-carbaldehyde
(5S,6S,7S,8R)-2-(2-phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-<2-(2-phenylethyl)chromonyl-6-oxy>chromone|(5S,6S,7S,8R)-2-(2-phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-[2-(2-phenylethyl)chromonyl-6-oxy]chromone|(5S,6S,7S,8R)-2-(2-Phenylethyl)-6,7,8-trihydroxy-5,6,7,8-tetrahydro-5-[2-(2-phenylethyl)chromonyl-6-oxy]chromone (AH14)|AH10
(1R,2S,4S,5S,6R,7S,8S,9R,10S)-1-acetoxy-9-benzoyloxy-8-trans-cinnamoyloxy-2,4,6-trihydroxydihydro-beta-agarofuran
(2R,3S,4S)-2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-4-[(4-hydroxy-3-methoxyphenyl)methyl]tetrahydrofuran 3-{[(2R)-2-carbomethoxy-2-hydroxy]ethyl}benzoate|hyosmin
(l(-)-tyrosyl)=>glutaminyl=>glutaminyl=>-glutamic acid|(l(-)-Tyrosyl)=>glutaminyl=>glutaminyl=>-glutaminsaeure
10-(6-O-trans-sinapoyl-beta-D-glucopyranosyl)gardendiol|11-(6-O-trans-sinapoyl-beta-glucopyranosyl)gardendiol
3beta-(beta-D-glucopyranosyloxy)-19-carboxy-14beta-hydroxycard-20(22)-enolide
12-O-butenoyl-5-hydroxy-6,7-epoxy-resiniferonol-9,13,14-orthobenzoate
4-methoxy-9,10-dihydrophenanthrene-2,7-di-O-beta-D-glucopyranoside
(2E)-1-{2,4-dihydroxy-6-methoxy-3-[(2R,4S,6S)-tetrahydro-2-(4-hydroxyphenyl)-6-(2-phenylethyl)-2H-pyran-4-yl]phenyl}-3-(4-hydroxyphenyl)prop-2-en-1-one|Katsumain D
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-4-[(2S)-2-hydroxy-4-(4-hydroxyphenyl)butyl]-2-(4-hydroxyphenyl)-7-methoxy-2H-1-benzopyran-6-yl}-3-phenylprop-2-en-1-one|katsumain E
(2E)-1-{(2R,4S)-3,4-dihydro-5-hydroxy-2-(4-hydroxyphenyl)-4-[(2S)-2-hydroxy-4-phenylbutyl]-7-methoxy-2H-1-benzopyran-6-yl}-3-(4-hydroxyphenyl)prop-2-en-1-one|katsumain G
(+)-lyoniresinol-3alpha-O-alpha-L-rhamonopyranoside
E-3-[3-(benzoyloxymethyl)-2-(4-hydroxy-3-methoxyphenyl)-7-methoxy-2,3-dihydrobenzo[b]furan-5-yl]prop-2-enyl benzoate
(aS)-(5R,6S,7R,8R)-8-benozyloxy-5,6,7,8-tetrahydro-1,5-dihydroxy-3,12-dihydroxy-1,2,10,11-tetramethoxy-6,7-dimethyldibenzo[a,c]cycloocten-5-yl acetate|kadsuphilin I
(20S,22S,23S,24S,25S,26S)-5alpha-chloro-12alpha,22-23,26,24,25-triepoxy-12-ethoxy-6beta,17beta,26-trihydroxyergosta-2-en-1-one|12-O-ethyl-jaborosalactol 25|12-O-ethyljaborosalactol 25
C30H43ClO8 (566.2646308000001)
10-(6-O-trans-sinapoyl-beta-glucopyranosyl)gardendiol|11-(6-O-trans-sinapoyl-beta-D-glucopyranosyl)gardendiol
(8R*,7S*,8R*)-5,5-dimethoxy-7-oxolariciresinol 9-O-beta-D-xylopyranoside
5-methylresveratrol-3,4-O-beta-D-diglucopyranoside
Asn Tyr Arg Asp
Asn Tyr Asp Arg
Tyr Thr Gln Arg
4-[4-(2,4-dihydroxy-3,6-dimethylbenzoyl)oxy-2-methoxy-3,5,6-trimethylbenzoyl]oxy-2-methoxy-3,5,6-trimethylbenzoic acid
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid
(8xi,11alpha,14xi,17alpha)-3-[(6-Deoxyhexopyranosyl)oxy]-5,11,14-trihydroxy-19-oxocard-20(22)-enolide
Origin: Plant, Cardanolides
3-[[6-[[1,4a-dimethyl-6-methylidene-5-[2-(5-oxo-2H-furan-4-yl)ethyl]-3,4,5,7,8,8a-hexahydro-2H-naphthalen-1-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-3-oxopropanoic acid_major
Ala Lys Trp Tyr
Ala Lys Tyr Trp
Ala Gln Trp Tyr
C28H34N6O7 (566.2488854000001)
Ala Gln Tyr Trp
C28H34N6O7 (566.2488854000001)
Ala Trp Lys Tyr
Ala Trp Gln Tyr
C28H34N6O7 (566.2488854000001)
Ala Trp Tyr Lys
Ala Trp Tyr Gln
C28H34N6O7 (566.2488854000001)
Ala Tyr Lys Trp
Ala Tyr Gln Trp
C28H34N6O7 (566.2488854000001)
Ala Tyr Trp Lys
Ala Tyr Trp Gln
C28H34N6O7 (566.2488854000001)
Cys Cys Arg Trp
C23H34N8O5S2 (566.2093474000001)
Cys Cys Trp Arg
C23H34N8O5S2 (566.2093474000001)
Cys Lys Met Trp
Cys Lys Trp Met
Cys Met Lys Trp
Cys Met Gln Trp
Cys Met Trp Lys
Cys Met Trp Gln
Cys Gln Met Trp
Cys Gln Trp Met
Cys Arg Cys Trp
C23H34N8O5S2 (566.2093474000001)
Cys Arg Trp Cys
C23H34N8O5S2 (566.2093474000001)
Cys Trp Cys Arg
C23H34N8O5S2 (566.2093474000001)
Cys Trp Lys Met
Cys Trp Met Lys
Cys Trp Met Gln
Cys Trp Gln Met
Cys Trp Arg Cys
C23H34N8O5S2 (566.2093474000001)
Asp Asn Arg Tyr
Asp Asn Tyr Arg
Asp Arg Asn Tyr
Asp Arg Tyr Asn
Asp Tyr Asn Arg
Asp Tyr Arg Asn
Glu Lys Gln Tyr
Glu Lys Tyr Gln
Glu Gln Lys Tyr
Glu Gln Gln Tyr
Glu Gln Tyr Lys
Glu Gln Tyr Gln
Glu Tyr Lys Gln
Glu Tyr Gln Lys
Glu Tyr Gln Gln
Phe His Thr Tyr
C28H34N6O7 (566.2488854000001)
Phe His Tyr Thr
C28H34N6O7 (566.2488854000001)
Phe Lys Ser Trp
Phe Met Asn Arg
Phe Met Arg Asn
Phe Asn Met Arg
Phe Asn Arg Met
Phe Asn Thr Trp
C28H34N6O7 (566.2488854000001)
Phe Asn Trp Thr
C28H34N6O7 (566.2488854000001)
Phe Gln Ser Trp
C28H34N6O7 (566.2488854000001)
Phe Gln Trp Ser
C28H34N6O7 (566.2488854000001)
Phe Arg Met Asn
Phe Arg Asn Met
Phe Ser Gln Trp
C28H34N6O7 (566.2488854000001)
Phe Ser Trp Gln
C28H34N6O7 (566.2488854000001)
Phe Thr His Tyr
C28H34N6O7 (566.2488854000001)
Phe Thr Asn Trp
C28H34N6O7 (566.2488854000001)
Phe Thr Trp Asn
C28H34N6O7 (566.2488854000001)
Phe Thr Tyr His
C28H34N6O7 (566.2488854000001)
Phe Trp Asn Thr
C28H34N6O7 (566.2488854000001)
Phe Trp Gln Ser
C28H34N6O7 (566.2488854000001)
Phe Trp Ser Gln
C28H34N6O7 (566.2488854000001)
Phe Trp Thr Asn
C28H34N6O7 (566.2488854000001)
Phe Tyr His Thr
C28H34N6O7 (566.2488854000001)
Phe Tyr Thr His
C28H34N6O7 (566.2488854000001)
His Phe Thr Tyr
C28H34N6O7 (566.2488854000001)
His Phe Tyr Thr
C28H34N6O7 (566.2488854000001)
His His His His
C24H30N12O5 (566.2462009999999)
His Pro Gln Trp
His Pro Trp Gln
His Gln Pro Trp
His Gln Trp Pro
His Thr Phe Tyr
C28H34N6O7 (566.2488854000001)
His Thr Tyr Phe
C28H34N6O7 (566.2488854000001)
His Trp Pro Gln
His Trp Gln Pro
His Tyr Phe Thr
C28H34N6O7 (566.2488854000001)
His Tyr Thr Phe
C28H34N6O7 (566.2488854000001)
Lys Cys Met Trp
Lys Cys Trp Met
Lys Glu Gln Tyr
Lys Glu Tyr Gln
Lys Met Cys Trp
Lys Met Trp Cys
Lys Gln Glu Tyr
Lys Gln Tyr Glu
Lys Trp Cys Met
Lys Trp Met Cys
Lys Tyr Glu Gln
Lys Tyr Gln Glu
Met Cys Lys Trp
Met Cys Gln Trp
Met Cys Trp Lys
Met Cys Trp Gln
Met Phe Asn Arg
Met Phe Arg Asn
Met Lys Cys Trp
Met Lys Trp Cys
Met Asn Phe Arg
Met Asn Arg Phe
Met Gln Cys Trp
Met Gln Trp Cys
Met Arg Phe Asn
Met Arg Asn Phe
Met Trp Cys Lys
Met Trp Cys Gln
Met Trp Lys Cys
Met Trp Gln Cys
Asn Asp Arg Tyr
Asn Asp Tyr Arg
Asn Phe Met Arg
Asn Phe Arg Met
Asn Phe Thr Trp
C28H34N6O7 (566.2488854000001)
Asn Phe Trp Thr
C28H34N6O7 (566.2488854000001)
Asn Met Phe Arg
Asn Met Arg Phe
Asn Arg Asp Tyr
Asn Arg Phe Met
Asn Arg Met Phe
Asn Arg Tyr Asp
Asn Thr Phe Trp
C28H34N6O7 (566.2488854000001)
Asn Thr Trp Phe
C28H34N6O7 (566.2488854000001)
Asn Trp Phe Thr
C28H34N6O7 (566.2488854000001)
Asn Trp Thr Phe
C28H34N6O7 (566.2488854000001)
Pro His Gln Trp
Pro His Trp Gln
Pro Gln His Trp
Pro Gln Trp His
Pro Trp His Gln
Pro Trp Gln His
Gln Ala Trp Tyr
C28H34N6O7 (566.2488854000001)
Gln Ala Tyr Trp
C28H34N6O7 (566.2488854000001)
Gln Cys Met Trp
Gln Cys Trp Met
Gln Glu Lys Tyr
Gln Glu Gln Tyr
Gln Glu Tyr Lys
Gln Glu Tyr Gln
Gln Phe Ser Trp
C28H34N6O7 (566.2488854000001)
Gln Phe Trp Ser
C28H34N6O7 (566.2488854000001)
Gln His Pro Trp
Gln His Trp Pro
Gln Lys Glu Tyr
Gln Lys Tyr Glu
Gln Met Cys Trp
Gln Met Trp Cys
Gln Pro His Trp
Gln Pro Trp His
Gln Gln Glu Tyr
Gln Gln Tyr Glu
Gln Arg Thr Tyr
Gln Arg Tyr Thr
Gln Ser Phe Trp
C28H34N6O7 (566.2488854000001)
Gln Ser Trp Phe
C28H34N6O7 (566.2488854000001)
Gln Thr Arg Tyr
Gln Thr Tyr Arg
Gln Trp Ala Tyr
C28H34N6O7 (566.2488854000001)
Gln Trp Cys Met
Gln Trp Phe Ser
C28H34N6O7 (566.2488854000001)
Gln Trp His Pro
Gln Trp Met Cys
Gln Trp Pro His
Gln Trp Ser Phe
C28H34N6O7 (566.2488854000001)
Gln Trp Tyr Ala
C28H34N6O7 (566.2488854000001)
Gln Tyr Ala Trp
C28H34N6O7 (566.2488854000001)
Gln Tyr Glu Lys
Gln Tyr Glu Gln
Gln Tyr Lys Glu
Gln Tyr Gln Glu
Gln Tyr Arg Thr
Gln Tyr Thr Arg
Gln Tyr Trp Ala
C28H34N6O7 (566.2488854000001)
Arg Cys Cys Trp
C23H34N8O5S2 (566.2093474000001)
Arg Cys Trp Cys
C23H34N8O5S2 (566.2093474000001)
Arg Asp Asn Tyr
Arg Asp Tyr Asn
Arg Phe Met Asn
Arg Phe Asn Met
Arg Met Phe Asn
Arg Met Asn Phe
Arg Asn Asp Tyr
Arg Asn Phe Met
Arg Asn Met Phe
Arg Asn Tyr Asp
Arg Gln Thr Tyr
Arg Gln Tyr Thr
Arg Thr Gln Tyr
Arg Thr Tyr Gln
Arg Trp Cys Cys
C23H34N8O5S2 (566.2093474000001)
Arg Tyr Asp Asn
Arg Tyr Asn Asp
Arg Tyr Gln Thr
Arg Tyr Thr Gln
Ser Phe Gln Trp
C28H34N6O7 (566.2488854000001)
Ser Phe Trp Gln
C28H34N6O7 (566.2488854000001)
Ser Gln Phe Trp
C28H34N6O7 (566.2488854000001)
Ser Gln Trp Phe
C28H34N6O7 (566.2488854000001)
Ser Trp Phe Gln
C28H34N6O7 (566.2488854000001)
Ser Trp Gln Phe
C28H34N6O7 (566.2488854000001)
Thr Phe His Tyr
C28H34N6O7 (566.2488854000001)
Thr Phe Asn Trp
C28H34N6O7 (566.2488854000001)
Thr Phe Trp Asn
C28H34N6O7 (566.2488854000001)
Thr Phe Tyr His
C28H34N6O7 (566.2488854000001)
Thr His Phe Tyr
C28H34N6O7 (566.2488854000001)
Thr His Tyr Phe
C28H34N6O7 (566.2488854000001)
Thr Asn Phe Trp
C28H34N6O7 (566.2488854000001)
Thr Asn Trp Phe
C28H34N6O7 (566.2488854000001)
Thr Gln Arg Tyr
Thr Gln Tyr Arg
Thr Arg Gln Tyr
Thr Arg Tyr Gln
Thr Trp Phe Asn
C28H34N6O7 (566.2488854000001)
Thr Trp Asn Phe
C28H34N6O7 (566.2488854000001)
Thr Tyr Phe His
C28H34N6O7 (566.2488854000001)
Thr Tyr His Phe
C28H34N6O7 (566.2488854000001)
Thr Tyr Gln Arg
Thr Tyr Arg Gln
Trp Ala Gln Tyr
C28H34N6O7 (566.2488854000001)
Trp Ala Tyr Gln
C28H34N6O7 (566.2488854000001)
Trp Cys Cys Arg
C23H34N8O5S2 (566.2093474000001)
Trp Cys Lys Met
Trp Cys Met Lys
Trp Cys Met Gln
Trp Cys Gln Met
Trp Cys Arg Cys
C23H34N8O5S2 (566.2093474000001)
Trp Phe Asn Thr
C28H34N6O7 (566.2488854000001)
Trp Phe Gln Ser
C28H34N6O7 (566.2488854000001)
Trp Phe Ser Gln
C28H34N6O7 (566.2488854000001)
Trp Phe Thr Asn
C28H34N6O7 (566.2488854000001)
Trp His Pro Gln
Trp His Gln Pro
Trp Lys Cys Met
Trp Lys Met Cys
Trp Met Cys Lys
Trp Met Cys Gln
Trp Met Lys Cys
Trp Met Gln Cys
Trp Asn Phe Thr
C28H34N6O7 (566.2488854000001)
Trp Asn Thr Phe
C28H34N6O7 (566.2488854000001)
Trp Pro His Gln
Trp Pro Gln His
Trp Gln Ala Tyr
C28H34N6O7 (566.2488854000001)
Trp Gln Cys Met
Trp Gln Phe Ser
C28H34N6O7 (566.2488854000001)
Trp Gln His Pro
Trp Gln Met Cys
Trp Gln Pro His
Trp Gln Ser Phe
C28H34N6O7 (566.2488854000001)
Trp Gln Tyr Ala
C28H34N6O7 (566.2488854000001)
Trp Arg Cys Cys
C23H34N8O5S2 (566.2093474000001)
Trp Ser Phe Gln
C28H34N6O7 (566.2488854000001)
Trp Ser Gln Phe
C28H34N6O7 (566.2488854000001)
Trp Thr Phe Asn
C28H34N6O7 (566.2488854000001)
Trp Thr Asn Phe
C28H34N6O7 (566.2488854000001)
Trp Tyr Ala Gln
C28H34N6O7 (566.2488854000001)
Trp Tyr Gln Ala
C28H34N6O7 (566.2488854000001)
Tyr Ala Gln Trp
C28H34N6O7 (566.2488854000001)
Tyr Ala Trp Gln
C28H34N6O7 (566.2488854000001)
Tyr Asp Asn Arg
Tyr Asp Arg Asn
Tyr Glu Lys Gln
Tyr Glu Gln Lys
Tyr Glu Gln Gln
Tyr Phe His Thr
C28H34N6O7 (566.2488854000001)
Tyr Phe Thr His
C28H34N6O7 (566.2488854000001)
Tyr His Phe Thr
C28H34N6O7 (566.2488854000001)
Tyr His Thr Phe
C28H34N6O7 (566.2488854000001)
Tyr Lys Glu Gln
Tyr Lys Gln Glu
Tyr Asn Asp Arg
Tyr Asn Arg Asp
Tyr Gln Ala Trp
C28H34N6O7 (566.2488854000001)
Tyr Gln Glu Lys
Tyr Gln Glu Gln
Tyr Gln Lys Glu
Tyr Gln Gln Glu
Tyr Gln Arg Thr
Tyr Gln Thr Arg
Tyr Gln Trp Ala
C28H34N6O7 (566.2488854000001)
Tyr Arg Asp Asn
Tyr Arg Asn Asp
Tyr Arg Gln Thr
Tyr Arg Thr Gln
Tyr Thr Phe His
C28H34N6O7 (566.2488854000001)
Tyr Thr His Phe
C28H34N6O7 (566.2488854000001)
Tyr Thr Arg Gln
Tyr Trp Ala Gln
C28H34N6O7 (566.2488854000001)
Tyr Trp Gln Ala
C28H34N6O7 (566.2488854000001)
Canescein
Cediranib maleate
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents
2-[(1E,3E)-5-(3,3-DIMETHYL-1-PROPYL-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)-1,3-PENTADIENYL]-3,3-DIMETHYL-1-PROPYL-3H-INDOLIUM IODIDE
8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-diMethylethyl)-1,1a,3,4,5,6,9,10,20,21,22,22a-dodecahydro-14-Methoxy-3,6-dioxo-, Methyl ester, (1aR,5S,8S,10R,18E,22aR)-
ethyl 3-(2-(((4-(ethoxy(imino)methyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoate hydrochloride
(2R)-1-(1H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,(2R)-1-(3H-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol,dihydrochloride
3beta-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-5,11alpha,14-trihydroxy-19-oxo-5beta-card-20(22)-enolide
(4aS,5S,12aS)-2-carbamoyl-6-[(2E)-3,7-dimethylocta-2,6-dienyl]-4a,5,10,11,12a-pentahydroxy-8-methoxy-3,12-dioxo-4,5-dihydrotetracen-1-olate
(4r,5s,6s,7r)-4,7-Dibenzyl-5,6-dihydroxy-1,3-bis[4-(hydroxymethyl)benzyl]-1,3-diazepan-2-one
C35H38N2O5 (566.2780577999999)
A 1,3-diazepanone ring with two 4-(hydroxymethyl)benzyl groups as substituents at positions N-1 and N-4, two benzyl groups at C-4 and C-7, and two hydroxy groups at C-5 and C-6 respectively. D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D000084762 - Viral Protease Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors
Dehydrodiconiferyl dibenzoate
A lignan that is 2,3-dihydro-1-benzofuran substituted by a (benzoyloxy)methyl group at position 3, a 4-hydroxy-3-methoxyphenyl group at position 2, a methoxy group at position 7 and a 3-(benzoyloxy)prop-1-en-1-yl group at position 5. It is isolated as a racemate from Euterpe precatoria and exhibits antiplasmodial activity.
Meclorisone dibutyrate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
N-[3-(dimethylamino)propyl]-N-(4-ethoxy-1,3-benzothiazol-2-yl)-4-[methyl-(phenylmethyl)sulfamoyl]benzamide
C29H34N4O4S2 (566.2021364000001)
Cyclopropyl-[5-[[4-[[4-(2-methoxyphenyl)-1-piperazinyl]-oxomethyl]-1-piperidinyl]sulfonyl]-2-methyl-2,3-dihydroindol-1-yl]methanone
(5S,6R,7E,9E,11Z,14Z)-6-{[(2R)-2-{[(4S)-4-azaniumyl-4-carboxylatobutanoyl]amino}-2-carboxylatoethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoate
1-[[(2S,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
N-[(2R,4aS,12aS)-5-methyl-6-oxo-2-[2-oxo-2-(3-propan-2-ylanilino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-cyanobenzamide
1-[[(2S,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
1-(3-methoxyphenyl)-3-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3,3,3-trifluoropropyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
1-[[(2R,3R)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
1-[[(2R,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
1-[[(2R,3R)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
1-[[(2R,3S)-10-[(4-chlorophenyl)sulfonylamino]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
C26H35ClN4O6S (566.1965720000001)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(2-pyridinylmethyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-methylbenzenesulfonamide
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(3-pyridinylmethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-1-phenylmethanesulfonamide
1-(2-fluorophenyl)-3-[(4R,7R,8S)-5-[(2-fluorophenyl)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]urea
6-[[10-Butanoyl-3-hydroxy-6-(2-hydroxypropyl)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-5-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
3,4,5-Trihydroxy-6-[[3-hydroxy-10-(3-hydroxybutanoyl)-2,2-dimethyl-8-oxo-6-propyl-3,4-dihydropyrano[3,2-g]chromen-5-yl]oxy]oxane-2-carboxylic acid
S-[2-[3-[[(2R)-2-hydroxy-3,3-dimethyl-4-phosphonooxybutanoyl]amino]propanoylamino]ethyl] (Z)-tetradec-9-enethioate
[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C25H43O12P (566.2492007999999)
S-tetradecanoyl-4-phosphopantetheine(2-)
An S-acyl-4-phosphopantetheine obtained by deprotonation of the phosphate OH groups of S-tetradecanoyl-4-phosphopantetheine; major species at pH 7.3.
leukotriene F4(2-)
A leukotriene anion obtained by deprotonation of the three carboxy groups and protonation of the glutamyl alpha-amino group of leukotriene F4; major species at pH 7.3.